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CASE REPORT Open Access
Perivascular epithelioid cell tumor of
the descending colon mimicking a
gastrointestinal stromal tumor: a
case report
Ryuta Iwamoto1,2, Tatsuki R. Kataoka1*, Ayako Furuhata1, Kazuo Ono2, Seiichi Hirota3, Kenji Kawada4,
Yoshiharu Sakai4 and Hironori Haga1
Abstract
Background: We present a case of perivascular epithelioid cell tumor (PEComa), which clinically and histologically
mimics a gastrointestinal stromal tumor (GIST).
Case presentation: A 42-year-old woman was found to have a mass in the left flank during her annual medical
checkup. Computed tomography examination revealed a submucosal tumor of the descending colon. Surgeons
and radiologists suspected that the lesion was a GIST, and left hemicolectomy was performed without biopsy.
Microscopic examination showed that the lesion was composed of spindle and epithelioid cells, which were
immunohistochemically negative for c-kit and positive for platelet-derived growth factor receptor (PDGFR) α.
Initial diagnosis of PDGFRα-positive GIST was made. However, gene analysis did not reveal mutations in PDGFRα.
Additional immunohistochemistry showed that tumor cells were positive for human melanin black 45 (HMB45),
melanA, and the myogenic marker calponin. A final diagnosis of PEComa was made.
Conclusion: PEComa should be included in the differential diagnosis of PDGFRα-positive spindle cell tumors in
the wall of the gastrointestinal tract.
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Background
Gastrointestinal stromal tumor (GIST) is the most com-
mon mesenchymal tumor in the walls of the gastrointes-
tinal tract [1]. GISTs typically harbor gain-of-function
type mutations in the KIT genes [2], and GISTs without
KIT mutations have gain-of-function type mutations in
the platelet-derived growth factor receptor (PDGFR) α
genes [3]. Expression of the two genes is mutually exclu-
sive [1–3]. Perivascular epithelioid cell tumor (PEComa)
is a less common mesenchymal tumor, expressing mela-
nocytic and myogenic markers such as actin, desmin,
calponin, human melanin black (HMB) 45, melanA, and
microphthalmia-associated transcription factor (MITF)
[4]. PEComa can occur in any organs, but is rarely de-
tected in the gastrointestinal wall [5]. Herein, we report
a case of PDGFRα-positive PEComa arising in the wall
of the descending colon.
Case presentation
A 42-year-old woman underwent abdominal ultrasonog-
raphy during her annual medical checkup and a mass in
her left flank region was identified. She was admitted to
the hospital for further examination. A computed tom-
ography scan and endoscopic examination revealed a
submucosal tumor in the wall of the descending colon.
Systemic magnetic resonance imaging and positron
emission tomography scans did not show any other le-
sions. The lesion was suspected to be a colonic GIST
and left hemicolectomy was performed. Upon macro-
scopic examination, the tumor was 5 cm in the greatest
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dimension, well-circumscribed but uncapsulated, and ex-
tended from the muscular propria into the subserosa
(Fig. 1a). The cut surface was hemorrhagic and necrotic
(Fig. 1b). Microscopically, the tumor cells consisted of
spindle and epithelioid cells with a granular cytoplasm
(Fig. 2a). Based on the clinical diagnosis of GIST, a panel
of immunohistochemistry including KIT, PDGFRα, dis-
covered on GIST-1 (DOG1), CD34, S100, desmin, and
Ki67 were performed. The tumor cells were positive for
PDGFRα (Fig. 2b) and negative for KIT (Fig. 2c), DOG1
(Fig. 2d), CD34, S100, and desmin. The Ki-67 index was
3% (Fig. 2e). We initially suspected the tumor to be a
PDGFRα-positive GIST. Mutational analysis did not re-
veal any mutation in PDGFRα or KIT, and suggested
the possibility of a low-grade tumor other than GIST.
Upon further examination, the tumor cells were found
to be positive for HMB45 (Fig. 2f ) and calponin
(Fig. 2g), and negative for melanA, MITF, SOX10, and
actin. These results were compatible with PEComa.
This tumor was immunohistochemically negative for
Fig. 1 Macroscopic findings. a Gross appearance. b Sliced specimens
Fig. 2 Histological findings. a Hematoxylin and eosin (H&E) staining. Two representative fields. Immunohistochemical specimens for b PDGFRα, c
KIT, d discovered on GIST-1 (DOG1), e Ki67, f HMB45, g Calponin, and h TFE3. Photos are ×200 magnification in a and ×100 magnification in b–h
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TFE3 (Fig. 2h), but did not show rearrangement of
TFE3 in fluorescence in situ hybridization (FISH) (data
not shown). The patient was alive without recurrence
5 months after the resection.
Discussion
PEComa is rare in the gastrointestinal tract. To the best
of our knowledge, only 36 cases of gastrointestinal
PEComa have been reported sporadically [6, 7]. Doyle et
al. performed a clinicopathologic study of 35 cases of
gastrointestinal PEComa [5]. The current case shows
similarities with previously reported cases of gastro-
intestinal PEComa, in terms of the clinicopathological
features and immunological profile. GIST does not
show immunoreactivity for melanocytic markers [8],
and expression of HMB45 is important to support the
diagnosis of PEComa. Metastatic melanoma is positive
for HMB45, but is also positive for S100 protein and
lacks expression of myogenic markers such as calponin.
Some cases of PEComa show gene rearrangement in-
volving TFE3, and strong nuclear TFE3 expression [4, 5].
In our case, TFE3 rearrangement was not detected by
FISH. This result is not incompatible with a diagnosis of
PEComa because most gastrointestinal PEComas are
negative for TFE3 [5]. Thus, TFE3 status may not be a
diagnostic clue in gastrointestinal PEComa.
The tumor cells in our case were partly epithelioid
and immunohistochemically PDGFRα-positive. These
phenotypes were thought to be compatible with the ini-
tial diagnosis of GISTs with a PDGFRα mutation [3, 9].
However, GISTs with a PDGFRα mutation most com-
monly arise in the stomach [9, 10], and the tumor is
typically DOG1-positive [11, 12]. In contrast to the case
of GISTs, PDGFRα positivity and mutations in PDGFRα
genes have not been reported in PEComas, to the best
of our knowledge. The status of PDGFRα in PEComa
should be further studied to diagnose PDGFRα-positive
mesenchymal tumors in the gastrointestinal tract. Both
GISTs and PEComas are treated with surgical resection
and chemotherapy. GISTs are susceptible to the tyro-
sine kinase inhibitor imatinib [10], although PEComas
are susceptible to another inhibitor, sirolimus [13].
Therefore, distinguishing between GISTs and PEComas
would be important for appropriate administration of
kinase inhibitors.
Conclusion
PEComa should be included in the differential diagnosis
of mesenchymal tumors in the wall of the gastrointes-
tine, even though tumor cells are immunohistochemi-
cally PDGFRα-positive. Mutational analysis should be
performed to confirm the diagnosis of GIST, even
though PDGFRα is immunohistochemically positive.
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